US2011301081A1PendingUtilityA1

Long-acting formulations of insulins

54
Assignee: BECKER REINHARDPriority: May 19, 2010Filed: May 18, 2011Published: Dec 8, 2011
Est. expiryMay 19, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:Reinhard BeckerAnnke FrickPeter BoderkeChristiane FürstWerner MullerKatrin TertschUlrich WernerPetra LoosIsabell Schöttle
A61P 5/50A61P 3/10A61P 3/08A61P 5/48A61K 47/26A61K 9/08A61K 38/28A61K 38/2278A61K 9/0019A61K 38/26A61K 47/10A61K 47/30A61K 47/02
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Claims

exact text as granted — not AI-modified
1 . An aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. 
     
     
         2 . The aqueous formulation of  claim 1  comprising 200 U/ml to 650 U/mL of insulin glargine [equimolar to 200-600 IU human insulin]. 
     
     
         3 . The aqueous formulation of  claim 1  comprising 700 U/ml to 1000 U/mL of insulin glargine [equimolar to 700-1000 IU human insulin]. 
     
     
         4 . The aqueous formulation of  claim 2  comprising 270-330 U/mL of insulin glargine [equimolar to 270-330 IU human insulin]. 
     
     
         5 . The aqueous formulation of  claim 4  comprising 300 U/mL of insulin glargine [equimolar to 300 IU human insulin]. 
     
     
         6 . The aqueous pharmaceutical formulation of  claim 1  comprising an analogue of exendin-4. 
     
     
         7 . The aqueous formulation of  claim 6 , wherein the analogue of exendin-4 is selected from a group comprising lixisentatide, exenatide and liraglutide. 
     
     
         8 . The aqueous formulation of  claim 7  comprising 0.1 μg to 10 μg lixisenatide per U insulin glargine. 
     
     
         9 . The aqueous formulation of  claim 8  comprising 0.2 to 1 μg lixisenatide per U insulin glargine. 
     
     
         10 . The aqueous formulation of  claim 9  comprising 0.25 μg to 0.7 μg lixisenatide per U insulin glargine. 
     
     
         11 . The aqueous formulation of  claim 1  comprising at least one excipient selected from a group comprising zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
     
     
         12 . The aqueous formulation of  claim 11  comprising 90 μg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/ml glycerol 85%. 
     
     
         13 . The aqueous formulation of  claim 11  comprising 90 μg/mL zinc, 2.7 mg/mL m-cresol, 20 μg/mL polysorbate 20 and 20 mg/mL glycerol 85%. 
     
     
         14 . The aqueous formulation of  claim 1 , wherein the pH is between 3.4 and 4.6. 
     
     
         15 . The aqueous formulation of  claim 14 , wherein the pH is 4. 
     
     
         16 . The aqueous formulation of  claim 14 , wherein the pH is 4.5. 
     
     
         17 . A method of treating Type I and Type II Diabetes Mellitus in a patient comprising administering to said patient an aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL. 
     
     
         18 . The method of  claim 17  wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
     
     
         19 . The method of  claim 17  wherein said pharmaceutical composition further comprises 0.1 μg to 10 μg lixisenatide per U insulin glargine. 
     
     
         20 . A method of extending the duration of exposure of a long acting insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient comprising administering to said patient an aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL. 
     
     
         21 . The method of  claim 20  wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
     
     
         22 . The method of  claim 20  wherein said pharmaceutical composition further comprises 0.1 μg to 10 μg lixisenatide per U insulin glargine. 
     
     
         23 . A method of reducing the incidence of hypoglycemia in the treatment of Type I and Type II Diabetes Mellitus in a patient comprising administering to said patient an aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL. 
     
     
         24 . The method of  claim 23  wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
     
     
         25 . The method of  claim 23  wherein said pharmaceutical composition further comprises 0.1 μg to 10 μg lixisenatide per U insulin glargine. 
     
     
         26 . A method of providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient comprising administering to said patient an aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL. 
     
     
         27 . The method of  claim 26  wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
     
     
         28 . The method of  claim 26  wherein said pharmaceutical composition further comprises 0.1 μg to 10 μg lixisenatide per U insulin glargine. 
     
     
         29 . The aqueous pharmaceutical formulation of  claim 1  comprising 250-500 U/mL [equimolar to 250-500 IU insulin] of insulin glargine. 
     
     
         30 . The aqueous formulation of  claim 2  comprising 500 U/mL insulin glargine [equimolar to 500 IU human insulin]. 
     
     
         31 . The aqueous formulation of  claim 3  comprising 1000 U/mL insulin glargine [equimolar to 100 IU human insulin].

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.